Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04126070 · ClinicalTrials.gov registry record · Phase 2
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
A Phase 2 study of Prostate Adenocarcinoma and Hormone Sensitive Prostate Cancer, sponsored by Xiao X. Wei, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 6
- Study locations
NCT04126070: Active Phase 2 study of Prostate Adenocarcinoma and Hormone Sensitive Prostate Cancer, sponsored by Xiao X. Wei, MD.
NCT04126070 is a Phase 2 study of Prostate Adenocarcinoma and Hormone Sensitive Prostate Cancer that is active but no longer recruiting, run by Xiao X. Wei, MD. The registered enrollment target is 60 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (72% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04126070, a Phase 2 study of Prostate Adenocarcinoma and Hormone Sensitive Prostate Cancer, is active but no longer recruiting, sponsored by Xiao X. Wei, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: * Androgen deprivation therapy (ADT) with a drug of your physician's choice. This may include leuprolide (Lupron), goserelin acetate (Zoladex), or degarelix (Firmagon). * Docetaxel * Nivolumab
Primary Outcome
Summarized as percentage with 80% two-sided exact binominal confidence interval (CI) for each cohort
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Nivolumab
- DRUG Androgen Deprivation Therapy
Study Locations (6)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
California
- University of California, San Diego - La Jolla
Florida
- H. Lee Moffitt Cancer Center - Tampa
Maryland
- The Johns Hopkins University School of Medicine - Baltimore
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-05-11 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT04126070 still lists
NCT04126070 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (72% lower).
The record links to 3 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT04126070 lists 6 locations in 5 states (Massachusetts, California, Florida).
Frequently Asked Questions
What is clinical trial NCT04126070 about?
NCT04126070 is a clinical study titled "Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors". This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: * Androgen deprivation therapy (ADT) with a drug of your physician's ...
What is the current status of trial NCT04126070?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-05-11. Estimated completion is 2026-06-30.
What conditions does trial NCT04126070 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer, Metastasis Prostate Adenocarcinoma.
What interventions are being tested in trial NCT04126070?
The interventions under investigation include: Docetaxel (DRUG), Nivolumab (DRUG), Androgen Deprivation Therapy (DRUG).
Who is sponsoring clinical trial NCT04126070?
This trial is sponsored by Xiao X. Wei, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04126070 being conducted?
This trial has 6 study locations across California, Florida, Maryland, Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04126070's enrollment target sits among peer trials
60 54th of 99 higher than 42 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI